For Investors


We are committed to providing pharma-grade medical cannabis and superior patient care, while balancing patient economics and returns to shareholders.

Current Stock Information


Aphria is the first public licensed medical cannabis producer to report positive cash flow from operations and
the first to report positive earnings in consecutive quarters.
March 4, 2019

Aphria Receives Health Canada License Amendment, Approving Fully Expanded Production at Aphria One

Aphria today announced that Health Canada has granted the Company its license amendment, permitting Aphria to commence production in an additional 800,000 square feet of facilities at its Aphria One location, as part of the Company’s completed Part IV and Part V expansions.
February 26, 2019
Aphria_Manna Press Release

Aphria Signs Worldwide License Agreement with Manna Molecular Science to Develop State-Of-The-Art Cannabis Transdermal Patches

Aphria today announced a worldwide license agreement with Manna Molecular Science, LLC, producers of state-of-the-art cannabis transdermal patches.
February 19, 2019

Aphria Announces Early Termination and Liquidation of Interests in Liberty Health Sciences, Inc.

Aphriatoday announced that independent members of its Board of Directors consisting of Shlomo Bibas, John Herhalt, Tom Looney and Irwin Simon, unanimously approved the early termination and liquidation of a promissory note, option and other agreements related to the Company’s previously announced divestment of all interests in Liberty Health Sciences, Inc.

Financial Information


We are committed to providing pharma-grade medical cannabis and superior
patient care, while balancing patient economics and returns to shareholders.
 
 

Notice and Access Disclosures


We are committed to providing pharma-grade medical cannabis and superior patient care, while balancing
patient economics and returns to shareholders.